Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fractyl Health, Inc. - Common Stock (NQ: GUTS )

3.990 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 3.990
Bid (Size) 3.500 (2)
Ask (Size) 6.380 (2)
Prev. Close 3.990
Today's Range 3.990 - 3.990
52wk Range 3.765 - 14.50
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day
Company will discuss recent corporate updates, including compelling preclinical data from Rejuva® pancreatic gene therapy platform, which was named top abstract at American Diabetes Association’s 84th... 
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates
From Fractyl Health, Inc.
Via GlobeNewswire

Performance

YTD
-68.95%
-68.95%
1 Month
-16.35%
-16.35%
3 Month
-38.99%
-38.99%
6 Month
-68.95%
-68.95%
1 Year
-68.95%
-68.95%

More News

Read More
Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President’s Select Oral Presentation at the American Diabetes Association’s
From Fractyl Health, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific Sessions
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024
From Fractyl Health, Inc.
Via GlobeNewswire
GUTS Stock Earnings: Fractyl Health Beats EPS for Q1 2024
Via InvestorPlace
Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D)
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health to Present at BofA Securities 2024 Health Care Conference
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting
From Fractyl Health, Inc.
Via GlobeNewswire
The 3 Most Volatile Stocks for Short-Term Traders: April 2024
Via InvestorPlace
Why Cal-Maine Foods Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Intel, XPeng And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes
From Fractyl Health, Inc.
Via GlobeNewswire
PVH Posts Q4 Results, Joins Humana, CVS Health And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
Why Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
From Fractyl Health, Inc.
Via GlobeNewswire
Top 5 Health Care Stocks Which Could Rescue Your Portfolio In March
Via Benzinga
UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
From Fractyl Health, Inc.
Via GlobeNewswire
Newly Listed Obesity Player Fractyl Health Shares Encouraging Preclinical Data
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.